– Reuters
Credit Suisse Initiates Coverage On Bristol-Myers Squibb with Neutral Rating, Announces Price Target of $78
Credit Suisse analyst Trung Huynh initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Neutral rating and announces Price Target of $78.